Calidi Biotherapeutics Valuation
| CLDI Stock | 0.83 0.03 3.49% |
Today, the firm appears to be undervalued. Calidi Biotherapeutics shows a prevailing Real Value of USD30.62 per share. The current price of the firm is USD0.83. Our model approximates the value of Calidi Biotherapeutics from analyzing the firm fundamentals such as Shares Outstanding of 7.17 M, return on asset of -1.2, and Shares Owned By Institutions of 3.15 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Calidi Biotherapeutics' valuation include:
Price Book 0.8553 | Enterprise Value | Enterprise Value Ebitda (1.64) | Price Sales 50.8277 | Trailing PE 2.2931 |
Undervalued
Today
Please note that Calidi Biotherapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Calidi Biotherapeutics is based on 3 months time horizon. Increasing Calidi Biotherapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Calidi Biotherapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Calidi Stock. However, Calidi Biotherapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.83 | Real 30.62 | Target 120.0 | Hype 0.9 |
The intrinsic value of Calidi Biotherapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Calidi Biotherapeutics' stock price.
Estimating the potential upside or downside of Calidi Biotherapeutics helps investors to forecast how Calidi stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Calidi Biotherapeutics more accurately as focusing exclusively on Calidi Biotherapeutics' fundamentals will not take into account other important factors: When choosing an evaluation method for Calidi Biotherapeutics, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Calidi Biotherapeutics Cash |
|
Calidi Biotherapeutics Total Value Analysis
Calidi Biotherapeutics is currently forecasted to have valuation of (1.15 M) with market capitalization of 5.92 M, debt of 7.04 M, and cash on hands of . The negative valuation of Calidi Biotherapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Calidi Biotherapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(1.15 M) | 5.92 M | 7.04 M |
Calidi Biotherapeutics Asset Utilization
One of the ways to look at asset utilization of Calidi is to check how much profit was generated for every dollar of assets it reports. Calidi Biotherapeutics shows a negative utilization of assets of -1.2 percent, losing USD0.012 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Calidi Biotherapeutics shows how discouraging it operates for each dollar spent on its assets.Calidi Biotherapeutics Profitability Analysis
Based on Calidi Biotherapeutics' profitability indicators, Calidi Biotherapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Calidi Biotherapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2010-12-31 | Previous Quarter -19.9 M | Current Value -20.9 M | Quarterly Volatility 7.5 M |
For Calidi Biotherapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Calidi Biotherapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Calidi Biotherapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Calidi Biotherapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Calidi Biotherapeutics over time as well as its relative position and ranking within its peers.
Calidi Biotherapeutics Earnings per Share Projection vs Actual
By analyzing Calidi Biotherapeutics' earnings estimates, investors can diagnose different trends across Calidi Biotherapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Calidi Biotherapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Calidi Biotherapeutics Ownership Allocation
Calidi Biotherapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.Calidi Biotherapeutics Profitability Analysis
Net Loss for the year was (22.21 M) with profit before overhead, payroll, taxes, and interest of 31 K.About Calidi Biotherapeutics Valuation
An absolute valuation paradigm, as applied to Calidi Stock, attempts to find the value of Calidi Biotherapeutics based on its fundamental and basic technical indicators. By analyzing Calidi Biotherapeutics's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Calidi Biotherapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Calidi Biotherapeutics. We calculate exposure to Calidi Biotherapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Calidi Biotherapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -1.4 M | -1.3 M | |
| Pretax Profit Margin | (649.52) | (617.04) | |
| Operating Profit Margin | (591.05) | (561.50) | |
| Net Loss | (649.80) | (617.31) | |
| Gross Profit Margin | (5.85) | (5.56) |
Calidi Biotherapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Calidi Biotherapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Calidi we look at many different elements of the entity such as Calidi's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Calidi Biotherapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Calidi Biotherapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Calidi Biotherapeutics' worth.Complementary Tools for Calidi Stock analysis
When running Calidi Biotherapeutics' price analysis, check to measure Calidi Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calidi Biotherapeutics is operating at the current time. Most of Calidi Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Calidi Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calidi Biotherapeutics' price. Additionally, you may evaluate how the addition of Calidi Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |